HOVON 150
A phase 3, multicenter, double-blind, randomized, placebo-controlled study of AG-120 or AG- 221 in combination with induction therapy and consolidation therapy followed by maintenance therapy in patients with newly diagnosed acute myeloid leukemia or myelodysplastic syndrome with excess blasts-2 with an IDH-1 or IDH-2 mutation eligible for intensive chemotherapy
Description: This trial assesses the effectiveness of AG-120 or AG- 221 in combination with induction therapy and consolidation therapy followed by maintenance therapy patients with newly diagnosed acute myeloid leukemia or myelodysplastic syndrome with excess blasts-2 with an IDH-1 or IDH-2 mutation eligible for intensive chemotherapy
Study Phase: Phase 3
Principal Investigator: Catherine Flynn
Further information
